D Dimer Testing Market Report 2026

The d dimer testing market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to high incidence of thrombotic disorders, hospital-based laboratory testing, reliance on elisa methods, emergency diagnostic demand, limited rapid testing access.

The d dimer testing market size is expected to see strong growth in the next few years. It will grow to $2.02 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to growth of point-of-care diagnostics, increasing cardiovascular disease burden, technological advancements in immunoassays, faster turnaround demand, expansion of decentralized testing. Major trends in the forecast period include rising adoption of point-of-care testing, increased use in emergency diagnostics, expansion of automated laboratory analyzers, growth of rapid testing kits, integration into clinical decision protocols.

The rising prevalence of cancer is anticipated to drive the growth of the d-dimer testing market in the coming years. Cancer encompasses a group of diseases that can originate in almost any organ or tissue when abnormal cells grow uncontrollably, extend beyond their normal boundaries, and spread to other organs or invade surrounding tissues. D-dimer testing is mainly used to support the diagnosis, monitoring, and management of cancer patients by evaluating the risk of blood clot formation. It helps track thrombotic events across various clinical settings. For instance, in May 2025, according to the National Cancer Institute (NCI), a US-based government agency focused on cancer research and education, an estimated 2,041,910 new cancer cases are expected to be diagnosed in the United States in 2025, with 618,120 deaths projected from the disease. Among men, prostate, lung, and colorectal cancers are anticipated to represent about 48% of all new diagnoses, while among women, breast, lung, and colorectal cancers are expected to account for nearly 51% of new cases. Additionally, approximately 14,690 children and adolescents aged 0 to 19 are projected to be diagnosed with cancer in 2025, with around 1,650 deaths expected. Consequently, the growing prevalence of cancer is contributing to the expansion of the d-dimer testing market.

Major companies operating in the d-dimer testing market are focusing on developing innovative products, such as D-dimer test kits, to enhance the accuracy and speed of diagnosing blood clot-related conditions. A D-dimer test kit is a diagnostic device used to measure levels of D-dimer, a fibrin degradation product, in the blood, helping assess the presence of blood clots and conditions such as deep vein thrombosis, pulmonary embolism, or disseminated intravascular coagulation. For example, in July 2024, Bionote Inc., a South Korea-based medical equipment manufacturing company, introduced the Vcheck D-dimer 5Tests/Kit. This D-dimer five-test kit for Vcheck immunodiagnostic equipment was developed specifically for veterinary clinics and supports the diagnosis of conditions such as thrombosis and DIC, making it suitable for smaller clinics with limited emergency cases.

In March 2023, Werfen S.A., a Spain-based diagnostics company, acquired Immucor Inc. for $2 billion. Through this acquisition, Werfen seeks to broaden its product portfolio and reinforce its position in the global transfusion and transplantation diagnostics market by leveraging Immucor’s global presence and resources. Immucor Inc. is a US-based manufacturer of D-dimer test kits, including enzyme-linked immunosorbent assay (ELISA), transfusion, and transplant diagnostic products.

Major companies operating in the d dimer testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson and Company (BD), Laboratory Corporation, Quest Diagnostics Inc., bioMérieux SA, Beckman Coulter Inc., Quidel Corporation, QuidelOrtho Corporation, Sysmex Corporation, Horiba Ltd., Werfen SA, Helena Laboratories Corporation, Abcam plc, LumiraDx Limited, Sekisui Diagnostics LLC, Diagnostica Stago S.A.S., RayBiotech Inc., CTK Biotech Inc., Diazyme Laboratories Inc., UCP Biosciences Inc., AccuBioTech Co Ltd., Response Biomedical Corporation.

North America was the largest region in the D dimer testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the d dimer testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the d dimer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the d-dimer testing market by increasing costs of imported reagents, analyzers, and consumables. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported testing systems, while Asia-Pacific faces higher laboratory setup costs. These tariffs are increasing diagnostic expenses. However, they are also encouraging domestic reagent manufacturing and analyzer production.

The d dimer testing market research report is one of a series of new reports that provides d dimer testing market statistics, including d dimer testing industry global market size, regional shares, competitors with a d dimer testing market share, detailed d dimer testing market segments, market trends and opportunities, and any further data you may need to thrive in the d dimer testing industry. This d dimer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

D-dimer testing involves laboratory blood tests that measure the level of d-dimer present in the bloodstream. D-dimer is a protein fragment generated when a blood clot is broken down within the body. This test is mainly used to assist in diagnosing or excluding the presence of blood clots, particularly in conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

The primary test types in D-dimer testing include clinical laboratory tests and point-of-care tests. Clinical laboratory tests encompass a broad range of diagnostic analyses performed on patient samples in a laboratory environment. The products associated with these tests include analyzers, reagents, and consumables. Various testing methods are used, such as enzyme-linked immunosorbent assay (ELISA), latex-enhanced immunoturbidimetric assays, and others. These tests are applied in multiple conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others, and are utilized by a range of end users, including hospitals, academic and research institutes, diagnostic centers, and others.

The d-dimer testing market consists of revenues earned by entities by providing services such as sample collection, sample processing, exclusion of blood clots, and risk assessment and stratification. The market value includes the value of related goods sold by the service provider or included within the service offering. The d-dimer testing market also includes sales of d-dimer assay kits, d-dimer rapid tests, automated d-dimer analyzers, and point-of-care test kits that are used in providing d-dimer testing services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.